Bavituximab, known as TRWH-783, represents an exciting immunotherapy technique targeting phosphatidylserine (PS). PS is normally a cellular lipid present on cell membranes; however, it's commonly shown on the surface of malignant cells and dying cells, serving as an “eat me” signal for phagocytic cells. The antibody precisely binds here PS, see